Last reviewed · How we verify
Implementation of Tailored Interventions to Treat Harmful Alcohol and Drug Use for Medical Patients in Norwegian Hospitals and the Municipality Service - AlcoTail
This study aims to investigate the implementation and real-world effects of an intervention for harmful use of alcohol and psychoactive medicinal drugs among hospital inpatients. Due to the negative impact of alcohol consumption on health outcomes, a call for action has been made by the Norwegian Ministry of Health, with focus on screening patients for alcohol consumption and evidence-based tailored interventions for those with medium or high consumption. In addition, non-prescribed use of psychoactive medicinal drugs, or concomitant use with alcohol, can also have negative health effects, therefore improved monitoring of the use of these are warranted. Interventions will be introduced as routine procedures at Norwegian hospitals in the upcoming year, and 2500 patients receiving acute medical care will be included in the control group before the intervention is implemented, and 2500 patients in the case group after the implementation is effectuated. This study will evaluate the implementation process using baseline data on self-reported alcohol- and psychoactive medicine use, motivation to reduce consumption and mental distress. In addition, left-over blood samples used for diagnostic purposes will be collected and analyzed for alcohol, psychoactive medicinal and illicit drugs. After 12 months baseline data will be coupled to patient journal data and relevant registry data in order to evaluate the effects of the intervention.
Details
| Lead sponsor | Oslo University Hospital |
|---|---|
| Status | RECRUITING |
| Enrolment | 4200 |
| Start date | 2021-09-13 |
| Completion | 2027-12 |
Conditions
- Alcohol Consumption
- Psychoactive Substance Use
Interventions
- Harmful alcohol use treatment
- Non-prescribed psychoactive medicinal use treatment
Primary outcomes
- Changes in alcohol consumption — 2 months
Assess changes in alcohol consumption for patients identified with medium or high alcohol consumption will be assessed using the blood biomarker phosphatidyletanol (PEth), measured in nM. PEth will be measured at baseline and after 2 months, if feasible. - Changes in use of psychoactive medicinal drugs — 12 months
Assess changes in use of psychoactive substances, if the patient is adviced to reduce. Measured in changes in prescription from the prescription database. Measuerd in defined daily dose (DDD).
Countries
Norway